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Abstract   
Extracellular matrix (ECM) bioscaffolds prepared from decellularized tissues have been 
used to facilitate constructive and functional tissue remodeling in a variety of clinical 
applications. The discovery that these ECM materials could be solubilized and 
subsequently manipulated to form hydrogels expanded their potential in vitro and in vivo 
utility; i.e. as culture substrates comparable to collagen or Matrigel, and as injectable 
materials that fill irregularly-shaped defects. The mechanisms by which ECM hydrogels 
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direct cell behavior and influence remodeling outcomes are only partially understood, 
but likely include structural and biological signals retained from the native source tissue. 
The present review describes the utility, formation, and physical and biological 
characterization of ECM hydrogels. Two examples of clinical application are presented 
to demonstrate in vivo utility of ECM hydrogels in different organ systems. Finally, new 
research directions and clinical translation of ECM hydrogels are discussed.  
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1. Introduction  
Hydrogels are defined as highly hydrated polymer materials (>30% water by weight), 
which maintain structural integrity by physical and chemical crosslinks between polymer 
chains [1]. The polymer chains can be synthetic [e.g., polyethylene oxide (PEO), 
poly(vinyl alcohol) (PVA), poly(acrylic acid) (PAA), poly(propylenefumarate-co-ethylene 
glycol) P(PF-co-EG)] or natural (e.g., alginate, chitosan, collagen, hyaluronic acid). 
Synthetic and natural hydrogels have been widely used to fill space, deliver bioactive 
molecules/drugs, and/or deliver cells to stimulate tissue growth [1].  
Many hydrogels have been derived from components of the extracellular matrix 
(ECM) such as collagen, hyaluronic acid and elastin or complex mixtures of ECM 
proteins such as Matrigel. The focus of the present review is ECM hydrogels and 
specifically, hydrogels that are 1) derived from decellularized mammalian tissue, and 2) 
enzymatically solubilized and neutralized to physiologic pH and temperature. Hence, 
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ECM materials that fulfill one of these criteria, such as decellularized tissues that are 
“gel-like” but not further solubilized (for example decellularized human lipoaspirate [2] , 
intervertebral disc [3, 4], and devitalized cartilage [5, 6]) are beyond the scope of this 
review. In contrast to hydrogels composed of individual ECM components, ECM 
hydrogels retain the full biochemical complexity of the native tissue, and unlike Matrigel, 
are not composed of a protein source that is a product of a tumorigenic cell line.  
 
To date, ECM hydrogels have been primarily used as 3D organotypic culture models 
and to stimulate tissue growth after injury. The present review describes the utility, 
formation and physical and biological characterization of ECM hydrogels. Two examples 
of clinical application in selected organ systems are presented. Finally, new research 
directions and clinical translation of ECM hydrogels are discussed.  
 
1.1. Why ECM?  
The ECM consists of the structural and functional molecules secreted by the 
resident cells of each tissue, hence the 3D organization and biochemical composition of 
the ECM is distinctive for each tissue type. ECM has been influencing cell behavior, 
dynamically and reciprocally [7] since single cell organisms evolved more than 600 
million years ago, and likely played a central role in the transition from unicellular 
organisms to multicellular organisms [8]. Mimicking aspects of the structure and 
composition of the ECM has guided the rational design of biomaterials over the past 
several decades in attempts to proactively influence cell behavior [9].  
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Although decellularization of tissue was first reported in 1973 as a technique to preserve 
tissue intended to be used as a protective barrier for burn patients [10], the first reported 
production of ECM by decellularization of a source tissue for subsequent use as a 
bioscaffold for tissue reconstruction was the use of small intestinal submucosa (SIS) for 
vascular applications  [11-15]. These initial studies removed cellular material while 
preserving the structural and functional proteins of the ECM such as 
glycosaminoglycans (GAGs), proteoglycans, and growth factors [16]. When processed 
appropriately, ECM materials harvested by such methods retain the biochemical 
complexity, nanostructure, and bioinductive properties of the native matrix, and have 
been shown to promote the in vivo creation of site-specific, functional tissue [17]. ECM-
derived materials are FDA-allowed, can be preserved and used ‘off the shelf,’ have 
been implanted in millions of patients to date; and have been extensively characterized 
in both the 2D sheet and powder forms [17, 18]. 
The discovery that ECM bioscaffolds could be transformed into hydrogels expanded 
their potential in vitro and in vivo utility [16]. For example, minimally invasive delivery 
becomes possible wherein a pre-gel viscous fluid is injected with a catheter or syringe 
and polymerizes at physiologic temperature into a hydrogel conforming to the shape of 
any defect site. Compared to suspensions of ECM powders, ECM hydrogels can be 
injected with a more homogenous concentration and with greater ease [19].  
Hydrogels derived from SIS and urinary bladder matrix (UBM) have been shown 
to retain the inherent bioactivity of the native matrix with the ability to promote 
constructive remodeling in heterologous tissue applications [16, 20-26]. In the last 
decade more than 70 papers have been published on the use of ECM hydrogels in 
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almost every organ system. The mechanisms by which the ECM hydrogel modulates 
cell behavior are not fully understood but likely include release of bound growth factors 
[27], cytokines, and chemokines [28], presentation of cryptic peptides [29-32], exposure 
of bioactive motifs, and as recently reported, through bioactive matrix-bound 
nanovesicles [33]. 
  
2. ECM Hydrogel Formation  
ECM hydrogel formation is a collagen-based self-assembly process that is 
regulated in part by the presence of glycosaminoglycans, proteoglycans, and ECM 
proteins [34]. Therefore, polymerization kinetics will be influenced by the native 
biochemical profile of the source tissue and of the proteins that remain after 
decellularization and solubilization. It is important to achieve sufficient cell removal from 
source tissues [35, 36] while maintaining ECM composition and ultrastructure. The 
choice of solubilization protocol is crucial to not adversely affect the ability to 
subsequently form an ECM hydrogel. Table 1 provides an overview of the many 
methods used to decellularize source tissues and solubilize the remaining ECM. ECM 
hydrogels are primarily derived from porcine tissue but some hydrogel types, e.g., 
adipose, tendon, umbilical cord are sourced from human tissue. 
Formation of a hydrogel involves two key steps: 1) solubilization of the ECM 
material into protein monomeric components, and 2) temperature- and/or pH-controlled 
neutralization to induce spontaneous reformation of the intramolecular bonds of the 
monomeric components into a homogeneous gel. The most prevalent method used to 
form an ECM hydrogel is via pepsin mediated solubilization of a comminuted (powder) 
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form of ECM (also called “ECM digestion”). Pepsin is an enzyme derived from porcine 
gastric juices that has been used since 1972 to solubilize a substantial portion (up to 
99%) of acid-insoluble collagen [37, 38]. Pepsin cleaves the telopeptide bonds of the 
collagen triple helix structure to unravel collagen fibril aggregates [39]. The ECM 
material is first powdered and stirred in pepsin with dilute hydrochloric acid over 48 
hours, as reported by Freytes et al. and designated herein as the “Freytes method” [20]. 
Another method involves the use of 0.5 M acetic acid instead of 0.1 M HCl as a base 
medium for the pepsin enzyme (“Voytik-Harbin method”) [16]. Pepsin digestion or 
solubilization is complete when the liquid is homogenous with no visible particles [20]. 
Different digestion times will produce a different profile of cryptic molecules, some of 
which possess bioactive properties [31, 40], suggesting the preferred digestion period 
will need to be tailored for each clinical application; times of 24 – 96 hours have been 
reported (Table 1). The “solubilized ECM” or “ECM digest” forms a gel when the liquid is 
neutralized to physiologic pH, salt concentration (“ECM pre-gel”) and temperature in 
vitro (“ECM hydrogel”) in an entropy-driven process dominated by collagen kinetics. 
Specifically, there is an increase in entropy when collagen monomers lose water, form 
aggregates, and bury surface-exposed hydrophobic residues within the fibril in vitro, in a 
self-assembly process [39, 41]. In practice, the “solubilized ECM” is neutralized to 
physiologic pH and salt concentration and kept at a low temperature well-below 37C, 
until the application of interest is identified for temperature-controlled gelation; e.g., 
injected by needle or catheter to gel in situ, or placed in an incubator for 3D cell culture.  
Johnson et al. investigated the effect of changing a single neutralization 
parameter (pH, temperature, ionic strength) from standard conditions (pH 7.4, 37°C, 1x 
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PBS) on the material properties of an ECM hydrogel, specifically myocardial ECM 
hydrogel [42]. In brief, the gelation time could be modulated from ~ 20 minutes at 
decreased salt concentration (0.5x PBS) or to > 8 hours at increased salt concentration 
(1.5x PBS). Increasing the salt concentration also decreased the storage modulus by ~ 
2-3 fold. Interestingly, lowering the gelation temperature below 22C was shown to 
inhibit gelation unlike pure collagen hydrogels that can gel between 4-37C. The impact 
of gelation parameters on material properties underscores the importance of 
understanding ECM hydrogel structure-function relationships. 
Alternative methods for ECM digestion include an extraction process to solubilize 
and form an ECM hydrogel from soft tissue [43, 44]. Proteins and glycoproteins can be 
extracted using a homogenization process involving pestle and mortar or high speed 
shear mixed within a high salt buffer that physically disrupts the ECM particles and 
collagen fiber structure at physiologic pH [43-47]. Homogenization involves a dispase 
enzymatic step that cleaves fibronectin, collagen IV, and collagen I and digests the 
ECM, a urea extraction step which further disrupts the non-covalent bonding and 
increases the solubility of the ECM proteins, and centrifugation that removes any 
residual non-soluble ECM components. The resulting solubilized extracts form an ECM 
hydrogel when increasing the temperature of the extract to 37C or by decreasing the 
pH with acetic acid to pH 4.0 (“Uriel method”) [43].  The Uriel method is based on the 
technique established to isolate commercial products Matrigel, Myogel, and Cartigel 
[44]. Basement membrane complexes are believed to be formed by cells secreting a 
certain threshold of basement proteins at 37C or by decreasing the local pH at the cell 
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surface to trigger laminin-111 arrangement; although the exact mechanism or 
combination thereof of pH and temperature gelation has yet to be determined [44]. 
While collagen kinetics and basement membrane assembly have been used to 
describe ECM hydrogel formation in vitro, the other components of the complex ECM 
unavoidably influence the hydrogel formation process. Brightman et al. showed that 
ECM hydrogels have distinct matrix assembly kinetics, fiber networks, and fibril 
morphology compared to purified collagen I hydrogels [34]. Addition of GAGs (heparin) 
or proteoglycans (decorin) to purified collagen I hydrogel show that the heparin moiety 
causes the collagen to gel faster and form larger fibers that are less tightly packed, 
while addition of decorin causes the collagen to gel faster but does not affect fibril 
network.  The results are consistent with the known role of heparin as a nucleation site 
for collagen fibrillogenesis and for decorin as a known regulator of fibril self-assembly 
[34, 39]. In addition to heparin and decorin, many other ECM proteins are known to 
contribute to collagen polymerization: fibronectin is known to organize collagen fibers, 
and minor collagens (collagen V and XI) are nucleation sites that must be present for 
collagen fibrillogenesis in vivo [48]. The Brightman et al. study [34] shows ECM 
glycoproteins and proteoglycans play a dynamic role in regulation of ECM hydrogel 
fibrillogenesis, and therefore the importance of preserving the ECM proteins in their 
stoichiometric ratios from the native tissues during the decellularization and 
solubilization steps (Table 1).  
 
3. ECM Hydrogel Characterization  
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Source tissue type and subsequent processing steps affect the topological, 
biochemical, mechanical, and biological properties of an ECM hydrogel. These 
properties have been well characterized for SIS and UBM hydrogels, as well as many 
different tissue-derived hydrogels. Figure 1 provides an overview of methods that have 
been used for various tissue types and is a general guide to the state of the field. Figure 
1 is not a comprehensive list since hydrogels made from various species, tissues, 
concentrations and processing methods have been classified only by the source tissue.  
There are certain characteristics of ECM hydrogels that are widely conserved 
regardless of source tissue; however, some properties vary markedly and are 
influenced by many factors, including source tissue, source species, ECM 
concentration, ECM processing method, method of sterilization, and even natural 
variability among biologic samples.  
 
3.1. Biochemical Composition 
The ECM is composed of a complex mixture of both structural and functional 
molecules that can be largely retained following the decellularization and solubilization 
processes if appropriate methods are used. However, the enzymatic solubilization 
process undoubtedly alters the proteins within the ECM hydrogel. Pouliot et al. directly 
compared the protein profile of lung ECM powder and pepsin digested lung ECM pre-
gel with SDS-PAGE [49]. The protein profile shows a smear of smaller proteins in the 
pre-gel solution, which must be due to fragmentation of larger proteins by the enzyme 
since there is no extraction or purification step involved in the pepsin-based 
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solubilization process. The extent to which this protein fragmentation affects the 
bioactivity of ECM hydrogels is currently unknown.  
Even so, the biochemical composition of the hydrogel forms of SIS [34] and UBM [20, 
23] are similar to that of the intact bioscaffolds with respect to collagen and sulfated 
GAG (sGAG) content. Intact SIS scaffolds are composed mainly of  collagen I with 
lesser amounts of collagens III, IV, V, and VI [17]. SIS hydrogels are known to at least 
contain collagens I, III, and IV and sGAGs [34]. Gel electrophoresis of UBM hydrogels 
shows similar bands to SIS hydrogels and both show additional bands corresponding to 
other ECM proteins [20]. Intact growth factors have also been confirmed in adipose [50], 
colon [51], liver [52], and SIS [53] ECM hydrogels, although present in reduced amounts 
compared to native tissue or ECM scaffolds. The impact of solubilization on cryptic 
peptide and matrix-bound nanovesicle content or activity has yet to be evaluated.  
In spite of the similarities, the composition of the ECM is distinctive for each tissue 
and organ. For example, the soluble collagen content of brain ECM is significantly less 
than UBM and spinal cord ECM [54], but that of dermis is significantly greater than UBM 
[23]. Both spinal cord and dermal ECM have lower sGAG content than UBM [54]. 
Species-specific differences in the composition of the same tissue type ECM, such as 
pericardium [55] and liver [56], have also been shown.  
A commonly used technique to characterize the biochemical composition of ECM 
hydrogels is mass spectroscopy. Reverse phase high-performance liquid 
chromatography interfaced with tandem mass spectroscopy (LC-MS/MS) was used to 
determine the proteomic profile of pepsin-solubilized hydrogels by comparing the 
generated protein fragments to a protein data bank. Thus far, LC-MS/MS has been 
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used to characterize liver [57], skeletal muscle [58], tendon [59], heart [55, 58, 60], 
kidney [61], pancreas [62] and umbilical cord [63] ECM hydrogels.  
 
3.2. Gel Ultrastructure 
 The native ECM structure is comprised of a 3D network of fibers with both tightly 
and loosely associated proteoglycans and GAGs. Fiber diameter, pore size, and fiber 
orientation can all influence cell behavior [44]. During the decellularization and 
solubilization processes, the collagen fiber structure is disrupted, resulting in loss of the 
native fiber network. The collagen monomers self-assemble into a fibrillar network which 
does not exist in the pre-gel solution [64]. Scanning electron microscopy (SEM) is the 
most common method of visualizing the topology of hydrogels, but transmission 
electron microscopy (TEM) [44], atomic force microscopy (AFM) [65], and confocal 
microscopy [34] have also been used. SEM images of fully-formed ECM hydrogels 
generally show a loosely organized nanofibrous scaffold with interconnecting pores [20]. 
The nano-scale topography provides a high surface area to volume ratio that allows 
increased area for integrin binding, and is small enough to be sensed and manipulated 
by infiltrating cells [42, 60]. An algorithm has been developed to perform automated and 
high-throughput analysis of SEM images with quantification of fiber diameter, pore size, 
and fiber alignment of hydrogels [23, 56, 66]. UBM hydrogels show an average fiber 
diameter of 74 nm [23]. Various source tissue ECMs showing an average fiber diameter 
of approximately 100 nm have been reported (e.g. cardiac [42], SIS [53], adipose [67]).  
As stated earlier, ECM hydrogels share many common features, but the tissue of 
origin, processing methods, and protein concentration of the hydrogel all influence the 
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structure of these materials. For example, pore size and fiber diameter are independent 
of concentration in UBM [23] and liver ECM gels [56], but vary with ECM concentration 
in dermal ECM gels [23]. UBM hydrogels also show randomly organized fibers, whereas 
more aligned fiber architecture has been observed in SIS hydrogels [53].  Qualitative 
analysis of SEM images show easily recognizable differences in structure depending 
upon the gelation mechanism (temperature- vs. pH-induced) used to create dermal 
hydrogels [44]. Variation in structure with species source has also been reported for 
liver hydrogels derived from human, rat, dog and pig [56].  
 
Some structural characteristics of the native ECM are retained in ECM hydrogels. 
For example the pore size, fiber diameter and primarily flocculent fiber structure of 
dermal ECM hydrogels are comparable to the native basement membrane [44]. 
Additionally, periodic striations characteristic of the D-band morphology of native 
collagen can be seen in fiber networks of liver [57] and tendon [59] hydrogels. 
 
3.3.  Viscoelastic Properties  
 
Low viscosity of the pre-gel solution and application-appropriate gelation kinetics are 
important criteria for minimally invasive delivery. Stated differently, sufficient time is 
required for delivery of the pre-gel to selected anatomic sites before gelation is 
complete.  Substrate stiffness is also known to direct stem cell differentiation and 
function in in vitro culture and also influences the remodeling outcome in vivo [68]. 
Therefore, use of an ECM hydrogel intended to define the microenvironment for stem 
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cell delivery or recruitment can be dependent upon pre-determined hydrogel properties. 
Furthermore, all three of these properties (i.e. pre-gel viscosity, gelation kinetics and gel 
stiffness) can affect whether the injected gel is retained within the defect site or instead 
diffuses into the surrounding host tissue [21, 22]. Turbidimetric gelation kinetics and 
rheology are the primary methods used to assess the viscoelastic properties of ECM 
hydrogels. Other methods, such as indentation [69] and compression [46, 64, 70] 
testing, AFM [65], and macroscopic rigidity [20, 23, 71] have been explored but will not 
be further reviewed herein.  
 
The turbidimetric gelation kinetics of UBM show a sigmoidal shape similar to that of 
purified collagen I gels [20]. Sigmoidal gelation behavior is also observed with bone 
[72], cartilage [70] and spinal cord ECM [54] hydrogels, whereas brain ECM hydrogels  
[54] show exponential behavior. The lag phase (tlag) and the time to reach half of the 
final turbidity (t1/2) is greater in UBM than collagen I gels, ostensibly due to the presence 
of GAGs and other molecules that may modulate self-assembly [20]. The tlag and t1/2 
vary with gelation mechanism [43, 44] and concentration [23, 71] in some cases, and 
are concentration-independent in others [70].  
Rheology is typically utilized to determine the storage modulus, or stiffness, of the 
hydrogel following gelation, but can also provide the pre-gel viscosity and time to 
gelation.  ECM pre-gel solutions show low viscosity that increases with protein 
concentration of the pre-gel [20, 22, 71]. Shear thinning behavior is also a common 
feature of ECM hydrogels, characterized by a decrease in the steady shear viscosity of 
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the pre-gel with increasing shear rate [73]. This characteristic may be desirable for ECM 
pre-gels intended for delivery through a catheter or syringe.  
Upon increasing the temperature from storage of the pre-gel at 4oC to 37°C, gelation 
of the ECM pre-gel is initiated and the resulting change in properties can be measured. 
The rate of gelation is greater with increasing concentration in UBM [23], bone [72], liver 
[57] and dermal [23] ECM hydrogels. The gelation time determined by rheology is also 
shorter than that determined by turbidimetric methods [20]. The final storage modulus is 
related to the stiffness, and solid-like behavior of the gel is confirmed when the storage 
modulus is greater than the loss modulus by approximately one order of magnitude, and 
the storage modulus is largely independent of frequency [20]. An increase in storage 
modulus occurs with increasing protein concentration for multiple source tissues 
including UBM [20, 22, 23], lung [49], heart [42], bone [72], colon [71], and liver [57]. 
Frequency sweep analysis after gelation shows very little frequency dependence of the 
storage modulus, indicative of a stable and uniform gel [22, 23, 57].  
A substantial strain-dependence is observed in some ECM hydrogels, with an 
increase in modulus occurring with increased strain [49, 72] and an irreversible change 
in modulus above 5% [49]. The storage modulus of hydrogels has been determined for 
gels formed directly on the rheometer, and for gels pre-formed in an incubator as long 
as 24 hours prior to rheological testing. The influence of strain and gelation method on 
observed modulus has yet to be studied, but the large variations could be partially due 
to different testing methods used by each group [49]. 
Table 2 shows the concentration, testing parameters, and final storage modulus of 
porcine-derived ECM hydrogels. The pre-gel steady shear viscosity and time to gelation 
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as determined by rheology are included where available. The dependence of storage 
modulus on source tissue, concentration, testing parameters and natural variability 
between samples is evident. The storage modulus of the ECM hydrogel is frequently 
lower than the respective tissue from which the hydrogel is derived. The hydrogel 
should be thought of, at least in part, as an inductive template to recruit cells that will 
secrete de novo ECM comprising the stiffness of the new tissue. Though ECM 
hydrogels derived only from porcine tissues are included in this table, species-
dependence of viscoelastic properties has also been noted [56].  
Another important ECM hydrogel design criterion is injectability. While injectability 
may be related to the viscoelastic properties (ECM pre-gel viscosity and gelation time), 
injectability has been independently confirmed in vitro and/or in vivo for heart [55, 60, 
74-81], spinal cord [82], small intestine [26, 51], umbilical cord [63], skeletal muscle [63, 
64, 83], tendon [59, 84], dermal [23], lung [49], liver [57], cartilage [70], urinary bladder 
[21, 22, 24, 82] and adipose [50, 67] ECM hydrogels with reported 18-27 gauge 
syringes or catheters. For example, porcine myocardial gel (6 mg/mL) was confirmed to 
be injectable through a 27 gauge catheter [75], and then confirmed to be injectable via 
NOGA guided MyoSTAR catheter (27 gauge), which is the current gold standard 
delivery device used in cellular cardiomyoplasty procedures [75]. The material remained 
injectable for 1 hour at room temperature during injection, a clear advantage compared 
to other natural materials such as collagen and fibrin that gel too quickly and cannot be 
delivered by catheter [75].  
 
4. Cellular Response to ECM Hydrogels 
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The ECM represents, in large part, the microenvironmental niche of every cell. The 
mechanism by which the native ECM influences cell behavior likely includes the 
physical and mechanical properties of the ECM, embedded cytokines and chemokines, 
cryptic peptides formed during ECM remodeling, and matrix-bound nanovesicle 
mediated events, among others. The signaling mechanisms that are preserved during 
production of an ECM hydrogel from a source tissue are only partially understood and 
will obviously influence cell viability, proliferation, migration, morphology, differentiation 
and phenotype. Established methods to evaluate the cellular response to ECM 
hydrogels both in vitro and in vivo are summarized in Figure 2.  
 The viability of cells cultured on the surface of ECM hydrogels in vitro has been 
consistently shown for cell lines [23, 54, 63, 64, 70, 71, 83], primary cells [57, 63, 69, 
71, 75, 83, 85], and stem cells [44, 49, 50, 73, 82, 86]. In addition, the innate bioactivity 
of soluble factors within the ECM has been demonstrated using in vitro culture with 
media supplemented with solubilized ECM to remove the influence of hydrogel structure 
on the function of cells.  
Wolf et al. studied the response of 3T3 fibroblasts and C2C12 myoblast cells to 
UBM and dermal ECM hydrogels by three different methods: cells seeded on the 
surface of pre-formed gels (ECM hydrogel substrate), cells embedded within gels (3D 
embedded), and gel placement in an anatomic defect site in vivo [23]. Almost 100% 
viability of 3T3 fibroblasts and C2C12 myoblasts was observed after 7 days of culture 
for all configurations investigated in vitro. C2C12 myoblast cells seeded on the surface 
of the dermal ECM hydrogels fused into large diameter, multinucleated myotubes with 
radial alignment, whereas cells cultured on the surface or embedded within UBM and 
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embedded within dermal ECM formed smaller elongated cell structures. Implantation of 
the hydrogels within a rodent partial thickness abdominal wall defect produced a 
significantly greater area of de novo muscle formation when the defects were treated 
with UBM hydrogel compared to unrepaired defects. This result likely represents the 
combination of microstructure, mechanical properties, and bioactivity. The collagen fiber 
ultrastructure and low storage modulus of UBM hydrogels allows for cell infiltration and 
fibroblast mediated contraction of the gel, two important aspects of wound healing [23].  
 
4.1 Comparison to Collagen and/or Matrigel  
Cell behavior in response to ECM hydrogels has consistently been shown to be 
comparable to Matrigel and/or collagen substrate for liver [87, 88], skeletal muscle [58], 
heart [58] and fat [43-45, 47, 67] applications. Uriel et al. [43] showed that primary rat 
pre-adipocytes cultured on the surface of adipose ECM hydrogels (1 mg/mL) formed 
colonies that were significantly larger compared to Matrigel (1 mg/mL) after 7 days 
indicative of enhanced pre-adipocyte differentiation. Furthermore, the adipose ECM 
hydrogels (1 mg/mL) that were formed by reducing pH to 4.0 showed significantly 
greater adipose area compared to Matrigel (1 mg/mL) at 1, 3, and 6 weeks in vivo in an 
epigastric pedicle model.  
 
5. In Vivo Applications of ECM Hydrogels 
Structure-function relationships of ECM hydrogels can provide a basis for predicting 
the appropriate hydrogel formulation for given applications. Although in vitro structure-
function relationships are important to understand, their relationship to in vivo 
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applications are largely unknown. There have been limited experiments with ECM 
hydrogels in two anatomic locations: the heart and the brain.  
 
5.1. Heart 
Cardiac-derived gels are being investigated for cardiac reconstruction following 
ischemic injury [42, 55, 58, 60, 75-78, 81]. Heterologous ECM hydrogels have been 
evaluated in the heart but formed cartilaginous tissue suggesting that tissue-specific 
cues may be necessary for appropriate cardiac tissue remodeling [75]. The Christman 
laboratory has investigated different cardiac tissue types for cardiac application 
including 1) the effect of species (porcine versus human) [60], and 2) the effect of 
pericardium versus myocardium [55].  
Both porcine and human source tissue has been evaluated for clinical translation. 
Porcine cardiac tissue is more homogeneous for variables such as diet, age, and strain 
unlike human cadaveric donor heart tissue which involves a range of ages, disease 
states, and co-morbidities [60, 76]. Alternatively, a human ECM source tissue has been 
cited as mitigating the risk for xenogeneic disease transfer [60], although there has not 
been a reported case of zoonotic disease in the millions of patients that have received 
porcine ECM scaffolds or porcine tissue (e.g., porcine heart valves) to date [89]. Both 
porcine and human myocardial ECM formed similar hydrogel ultrastructure in vivo after 
injection into the rat left ventricular myocardium [60]. However, perhaps most 
importantly, over half of the human myocardial pre-gel solutions did not form gels even 
allowing for the same DNA and lipid content. The differences may be attributed to the 
requirement for a “more harsh” decellularization protocol (e.g., longer SDS incubation, 
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lipid/DNA removal steps) required as a result of the increased ECM crosslinking and 
adipose tissue of the human tissue (donor age of human tissue ranged from 41-69 
years). Johnson et al. eventually recommended porcine myocardial ECM hydrogel as 
the preferred source for clinical translation over human myocardial ECM hydrogel 
because of the increased tissue availability, relatively more gentle decellularization 
protocol, and more reliable gelation [60]. Human tissue was recommended as a useful 
model system for in vitro study of the role of human ECM in cardiac disease. 
Two different tissue types within the heart were evaluated for myocardial repair. 
The pericardium is the fibrous sac surrounding the heart primarily composed of compact 
collagen and elastin fibers. While not tissue specific, the pericardium was explored as a 
potentially autologous therapy because the pericardium can be resected from the heart 
without adverse effect on heart function and is currently FDA approved for structural 
reinforcement in other body applications. The pericardial ECM hydrogel (6.6 mg/mL) 
and myocardial ECM hydrogel (6 mg/mL) were evaluated in the non-diseased, 
orthotopic location, and injected into the rat LV wall in separate studies. Both pericardial 
ECM and myocardial ECM hydrogels supported vascular cell infiltration (endothelial 
cells, smooth muscle cells) and almost identical arteriole formation within 2 weeks (51 
+/- 42 vessels/mm2, 52+/- 20 arterioles/mm2 respectively) [55, 75]. In conclusion, it was 
suggested that pericardial ECM may be a candidate for same-patient ECM sourcing [55, 
76], but myocardial ECM hydrogel was preferred for pre-clinical studies in the rat and 
pig.  
Porcine myocardial ECM hydrogel has been evaluated in both small and large 
animal models of myocardial infarction (MI). The in vivo pathogenic microenvironment 
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poses unique challenges such as the sustained release of pro-inflammatory cytokines 
thought to promote cell apoptosis or necrosis, matrix metalloproteinase (MMP) 
production that degrades the matrix, and an ischemic/hypoxic microenvironment. 
Myocardial ECM preserved cardiac function in a rat model of MI while the saline treated 
rats worsened 4 weeks after injection compared to baseline 1 week prior to injection. 
Specifically, myocardial ECM showed an increased ejection fraction (EF) and a 
relatively decreased percent change in end-systolic volume (ESV) and end-diastolic 
volume (EDV) compared to saline treated control; however, none of the three markers 
were significantly different compared to controls [79]. In an established large animal 
model, the myocardial ECM was delivered by the clinical standard transendocardial 
catheter two weeks after MI. After three months, myocardial ECM treated groups 
showed significant improvement in three measures of cardiac function: 1) 
echocardiography, 2) global wall motion index scoring, and 3) electromechanical NOGA 
mapping [77]. Corroborating the functional improvement, myocardial ECM treated 
animals promoted healthy muscle and blood vessel formation in infarcted areas: a 
distinct band of muscle that stained positive for troponin T below the endocardium was 
present in the myocardial ECM treated groups, and the muscle was significantly larger 
than control muscle.  The myocardial ECM treated group showed significantly reduced 
fibrosis and neovascularization foci below the endocardium compared to controls. 
Recently, Wassenaar et al. investigated the molecular mechanisms underlying 
the ability of myocardial ECM to mitigate negative LV remodeling using whole 
transcriptome analysis in the rat model of MI [81]. This was the first study to determine 
global gene expression changes with ECM hydrogel treatment.  The myocardial ECM 
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compared to saline control after 1 week of treatment showed several significantly 
altered pathways at the tissue level including: altered inflammatory response; 
decreased cardiomyocyte apoptosis, altered myocardial metabolism, enhanced blood 
vessel development, increased cardiac transcription factor expression, and increased 
progenitor cell recruitment. Angiogenesis is one of the processes modulated by ECM 
hydrogel treatment and a critically important process relevant to other in vivo 
applications. Wassenaar et al. speculate the ECM hydrogel may directly recruit 
endothelial progenitor cells through pro-angiogenic growth factors or matricryptic 
peptides, provide a scaffold for blood vessel formation, or modulate the recruited 
macrophages’ secretory profile [81]. 
 
 
5.2. Brain   
While the use of homologous ECM has been investigated for cardiac 
applications, the use of heterologous ECM, specifically UBM hydrogel, has been 
evaluated in brain applications to treat traumatic brain injury (TBI) [24] and stroke [21, 
22].  
In a rat model of TBI [24], UBM hydrogel (5 mg/mL) was delivered one day after 
controlled cortical impact injury. UBM mitigated adverse tissue damage with decreased 
lesion volume, decreased white matter injury, and increased vestibulomotor function at 
21 days. However, no cognitive improvement was shown by the Morris water maze 
task. While the UBM hydrogel showed functional improvement in tissue repair, it has yet 
to show the “holy grail” of cognitive improvement. It was suggested the brain may be a 
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type of clinical application which requires the addition of neural stem cells to the ECM 
hydrogel, or other tailoring of ECM hydrogel properties.  
ECM concentration-specific properties of UBM hydrogels were also used to 
selectively affect the material retention [22] and the immune cell infiltrate [21] in a small 
animal model of chronic stroke. Specifically, UBM hydrogel (1-8 mg/mL) was delivered 
14 days after middle cerebral artery occlusion in the rat. UBM hydrogels < 3 mg/mL did 
not form a gel within the stroke lesion and instead diffused into the surrounding brain 
tissue as early as 24 hours, the earliest time point investigated [22]. In a follow-up study, 
it was shown that with the use of UBM hydrogels < 3 mg/mL, the cells did not have a 
medium through which to infiltrate the lesion and instead accumulated around the lesion 
site [21]. UBM hydrogels > 3 mg/mL formed a hydrogel within the stroke cavity that 
interfaced with the adjacent tissue [21, 22]. Because a distinct host/tissue interface was 
formed, > 3 mg/mL treatment also showed extensive cell infiltration 1 day after delivery 
[21]. Macrophages and microglia were accompanied by neural progenitor cells, 
endothelial cells, oligodendrocytes, and astrocytes. An understanding of the cell 
infiltrate based upon the viscoelastic properties of the hydrogel in the brain is crucial 
since these cells will ultimately remodel the ECM and replace it with de novo matrix. 
While this application would suggest that the > 3 mg/mL UBM hydrogels would be 
preferred, other tissue applications may show improved outcomes if ECM signaling 
molecules would be released and permeate the surrounding tissue. 
For ECM hydrogels > 3 mg/mL that may be retained within the lesion and allow 
for immune cell infiltration, there are several concentration-dependent properties that 
may be important in the context of clinical delivery [22]. Four and 8 mg/mL UBM 
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hydrogels were tested in vitro as candidates for brain repair after stroke injury. Both 4 
and 8 mg/mL hydrogels showed ideal properties of an injectable therapy: viscosities 
ranging from that of water to honey (0.084 Pa*s and 0.443 Pa*s respectively), stably 
formed gels (G’ > G’’ by ~ 10 fold), and 50% gelation times (~3 min) considered to be a 
reasonable time frame in the operating room. The storage moduli or “stiffness” differed 
more dramatically for the 4 and 8 mg/mL hydrogel, at 76 and 460 Pa respectively. Brain 
tissue storage moduli has been reported between 200-500 Pa as a target moduli range 
[22], however it is important to state again the recruited cells will ultimately remodel the 
matrix.  
 
5.3. Safety  
The in vivo safety of an ECM hydrogel for any clinical application is obviously an 
important consideration. ECM hydrogels were considered safe in the aforementioned 
heart and brain in vivo applications. The ECM treated MI induced pigs did not show 
arrhythmias, thromboembolism or ischemia 3 months after myocardial ECM injection 
[77]. Hemocompatibility was further corroborated in vitro when the myocardial ECM gels 
were tested at a physiologically relevant concentration and shown not to accelerate 
coagulation.  
Zhang et al. also showed that the UBM hydrogel (5 mg/mL) did not have a 
deleterious effect when injected into the normal brain [24]. There was no reactive 
astrocytosis (GFAP+), and no neuronal degeneration at 1, 3, and 7 days after UBM 
hydrogel injection. Microglial activation and degenerate neurons were shown at 1 and 3 
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days along the needle track and injection site, but was no different than PBS control; 
and was resolved by 21 days. 
The potential unintended presence of ECM hydrogels in peripheral organs was 
evaluated in the studies of myocardial injection, and would be a safety concern relevant 
to all ECM hydrogel applications. Myocardial ECM hydrogels were not found at 2 hours 
in the pig lung, liver, spleen, kidney and brain [79], nor at 3 months [77]. Each clinical 
application of ECM hydrogels would likely have a distinctive profile of safety measures.  
5.4. In vivo Host Response 
The clinical applications of ECM involving the heart and brain did not elicit an 
adverse immune response. In general, ECM hydrogels have been well-tolerated in a 
wide variety of in vivo applications. No adverse immune response was shown after ECM 
hydrogels were injected in the heart [55, 60, 75-81], fat [43, 45, 47, 50, 67], liver [57], 
brain [21, 22, 24] skeletal muscle [23, 63, 64, 83], tendon [26, 59, 84], spinal cord [82], 
lung [49], cartilage [70], or colon [51, 71], and these studies included both homologous 
and heterologous ECM hydrogels. The findings in vivo are consistent with in vitro 
studies that have shown the pepsin-digested ECM (“pre-gel”) promotes a regulatory 
(“M2-like”) macrophage activation state, which is associated with a constructive 
remodeling response in vivo [71, 90, 91]. For example, macrophages activated toward 
an M2-like phenotype with solubilized ECM promoted downstream effects such as 
stimulating the migration and myogenesis of skeletal muscle progenitor cells [90]. In SIS 
hydrogel treatment of ulcerative colitis in vivo, the ECM modulated the macrophage 
response towards a predominately regulatory state by decreasing the number of pro-
inflammatory (“M1-like”) activated macrophages, as opposed to increasing the number 
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of M2-like macrophages [71]. This effect of altering the innate immune response by 
shifting the M2:M1 ratio is observed in the host response to solid ECM scaffolds as well 
[90].  
 
 
5.5  Summary of In vivo Applications  
Heart and brain were selected as two organ systems with a need for a minimally 
invasive, injectable therapy. The heart showed safety and efficacy of myocardial ECM 
hydrogel in small and large animal model of disease up to 3 months, and is currently 
being evaluated in a Phase I clinical trial (ClinicalTrial.gov Identifier: NCT02305602) 
[92]. The brain case study showed the importance of investigating multiple ECM 
concentrations to determine preferred characteristics of an injectable therapy for central 
nervous system (CNS) applications, including delivery, facilitation of the immune cell 
infiltrate, and mitigation of the default response to injury. Future work in the brain will 
likely identify the balance of factors required for cognitive improvement. Overall, each 
new therapeutic application will need a thorough understanding of the ECM hydrogel 
structure-function relationships for successful clinical translation. Relevant references to 
other organ in vivo applications can be found in Figure 1. 
 
6. Future Perspectives  
With more than 70 papers published in the last decade it is evident that the 
therapeutic potential of ECM hydrogels is recognized.  Characterization of hydrogel 
structure and function in vitro have provided a basis for selection of appropriate source 
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tissue and hydrogel formulation in selected body systems.  However, the relationship 
between in vitro structure-function and in vivo application is still largely unknown for 
most other clinical applications.  
The mechanisms by which ECM hydrogels mediate cell behavior are not fully 
understood. Several hypotheses have been suggested including the possibility that the 
architecture of the gelled hydrogel comprises a pore size and fiber diameter suitable for 
endogenous cell infiltration [93]. Additionally, the bioinductive hydrogel provides tissue-
specific cues, likely through the release of bound growth factors [27], or the creation of 
cryptic peptides or the exposure of bioactive motifs [29-32]. The recent report of 
bioactive matrix-bound nanovesicles within biologic scaffolds [33] provides a new 
possibility for study to determine the mechanisms contributing to the constructive tissue 
remodeling facilitated by ECM hydrogels. 
The use of ECM hydrogels as a delivery vehicle is an obvious area for future study. 
Although a standalone ECM biomaterial therapy offers practical advantages by way of 
reduced regulatory concerns, ease of manufacturing and route to market, combinations 
of ECM hydrogels with growth factors and/or cells may provide significant mutual 
enhancement. Recent studies have shown that sulfated GAGs within ECM hydrogels 
bind to growth factors with prolonged release of basic fibroblast growth factor and 
heparin-binding growth factor that enhances therapeutic effects [78, 94]. ECM hydrogels 
have also been used as a delivery system for growth factor containing microparticles to 
enhance skeletal tissue repair within an ex vivo chick femur defect model [95].  Cell 
therapy for neurological conditions may require integration with an appropriate 
biomaterial to support cells during transplantation and provide a structural support 
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system post implantation. Recent investigations of ECM hydrogels for CNS applications 
have included the assessment of different source tissues to direct cell differentiation [96] 
and the transplantation of human neural stem cells embedded within ECM hydrogels to 
support the creation of de novo tissue [25]. Stem cells and primary cells have also been 
embedded within lung [49], liver [57], spinal cord [82], and adipose [50] ECM hydrogels 
to improve the tissue remodeling outcome.   
 In conclusion, the use of ECM hydrogels for a variety of clinical applications is in 
its infancy, but has shown promise. The combination of in vitro and in vivo studies 
designed to understand mechanical and material properties, the effects of processing 
methods upon hydrogel performance, the mechanisms by which such hydrogels 
influence cell behavior and tissue remodeling, and the safety of ECM hydrogels should 
advance their clinical utility.  
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Tables & Figures  
Table 1. Decellularization reagents and solubilization protocol used to produce ECM 
hydrogels for each source tissue and species. The fundamental solubilization protocols 
are referred to as Voytik-Harbin, Freytes and Uriel as defined below. Any modifications 
to the base protocol are indicated within the table.  
 
 
 28 
Source Tissue Decellularization Reagents 
Solubilization 
Protocol 
Ref. 
Adipose 
Human 
(Lipoaspirate) 
 
 1% SDS, or 2.5 mM sodium 
deoxycholate 
 2.5 mM sodium deoxycholate with 500 
U lipase and 500 U colipase 
 Freytes 
 3200 IU pepsin 
 0.1 M HCl 
[67] 
 0.5% SDS 
 Isopropanol 
 0.1% peracetic acid/4% ethanol 
 Voytik-Harbin 
 10 mg pepsin 
 RT, 48 hr 
[73] 
Rat 
(Subcutaneous) 
 2 mL dispase/ g tissue   Uriel 
[43, 
44, 
47] 
Porcine 
 10 mM Tris and 5 mM EDTA 
 99% isopropanol 
 HBSS with 10000 U DNase, 12.5 mg 
RNase, 1000 U lipase 
 Freytes 
 37oC, 24 hr 
[97] 
Bone 
Bovine 
(Cancellous Tibia) 
 0.5 M HCl 
 1:1 Chloroform:methanol 
 0.05% trypsin/0.02% EDTA 
 1% w/v pen/strep in PBS 
 Freytes 
 96 hr 
[72, 
86, 
98] 
Cartilage 
Porcine 
(Articular) 
 
 10 mM Tris-HCl at pH 8 
 0.25% trypsin 
 1.5 M NaCl in 50 mM Tris-HCl at pH 7.6 
 50 U/mL DNase and 1 U/mL RNase in 
10 mM Tris-HCl 
 1% Triton X-100  
 10 mM Tris-HCl 
 0.1% peracetic acid/4% ethanol 
 Voytik-Harbin 
 10 mg pepsin 
 RT, 48 hr 
[73] 
Porcine 
(Meniscus) 
 1% SDS 
 0.1% EDTA 
 Freytes 
 1.5 mg/mL pepsin 
[70] 
Central Nervous System 
Porcine 
(Adult Brain, Spinal 
Cord) 
 0.02% trypsin/0.05% EDTA 
 3% Triton X-100 
 1 M sucrose 
 4% deoxycholate 
 0.1% peracetic acid/4% ethanol 
 Freytes 
[54, 
82, 
91, 
99] 
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Porcine 
(Fetal Brain) 
 0.05% trypsin-EDTA with 0.2% DNase I 
 3% Triton X-100 with 0.2% DNase I 
 1 M sucrose 
 1% sodium deoxycholate 
 0.2% peracetic acid in 4% ethanol 
 Freytes 
 24 hr 
[100] 
Colon 
Porcine 
(Submucosa) 
 2:1 Chloroform:methanol 
 Graded ethanol (100%, 90%, 70%) 
 0.02% trypsin/0.05% EDTA 
 4% sodium deoxycholate 
 0.1% peracetic acid/4% ethanol 
 Freytes 
 0.1 M HCl 
[71] 
Cornea 
Porcine 
 10 U/ml DNAse and 10 U/mL RNAse in 
10 nM MgCL2 
 Freytes 
 0.1 M HCl 
 72 hr 
[69] 
Esophagus 
Porcine 
(Mucosa/submucosa) 
 1% trypsin/0.05% EDTA 
 1 M sucrose 
 3% Triton X-100 
 10% deoxycholate 
 0.1% peracetic acid/4% ethanol 
 Freytes 
[101] 
Heart 
Porcine, Rat 
(Ventricular 
Myocardium) 
 1% SDS  
 1% Triton X-100 
 Freytes 
 0.1 M HCl 
[58, 
74, 
75, 
77, 
79, 
81, 
102] 
Porcine 
(Ventricular 
Myocardium) 
 
 1% SDS and 0.5% pen/strep 
 Freytes 
 0.1 M HCl 
[42, 
60, 
80, 
103-
106] 
 1% SDS 
 1% Triton X-100 
 0.1% peracetic acid/4% ethanol 
 Voytik-Harbin 
 10 mg pepsin 
 RT, 48 hr 
[73, 
107] 
 0.02% trypsin-EDTA 
 3% Tween-20 
 102 mM sodium deoxycholate 
 0.1% peracetic acid 
 Freytes 
[108] 
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 1% pen/strep 
 1% SDS 
 0.1% Triton X-100 
 Freytes 
 0.1 M HCl 
 12 hr 
[109] 
Perfusion 
 0.02% trypsin/0.05% EDTA 
 3% Triton X-100/0.05% EDTA 
 4% deoxycholic acid 
 0.1% peracetic acid 
 2:1 chloroform:methanol 
 100-70% ethanol 
 Freytes 
 2 mg/mL pepsin 
[110] 
Human 
(Ventricular 
Myocardium) 
 1% SDS and 0.5% pen/strep 
 Isopropyl alcohol 
 40 U/mL DNase and 1 U/mL RNase in 
40 mM HCl, 6 mM MgCl2, 1 mM CaCl2, 
and 10 mM NaCl  
 1% SDS/0.5% pen/strep 
 0.001% Triton X-100 
 Freytes 
[60] 
 10 mM Tris and 0.1% EDTA 
 0.5% SDS 
 100 U/mL pen/strep and nystatin in 
DPBS 
 Fetal bovine serum 
 100 U/mL pen/strep and nystatin in 
DPBS 
 Freytes 
 pH 1 
 37oC 
 Salts were not 
neutralized 
[111] 
 10 mM Tris and 0.1% EDTA 
 0.5% SDS 
 100 U/mL pen/strep and nystatin in 
DPBS 
 Fetal bovine serum 
 100 U/mL pen/strep and nystatin in 
DPBS 
 Freytes 
 pH 2 
[111] 
Goat 
(Ventricle) 
 0.1% peroxyacetic acid/4% ethanol 
 1% SDS 
 1% Triton X-100 
 Freytes 
 60-72 hr 
[112] 
Porcine, Human 
(Pericardium) 
 1% SDS 
 Freytes 
 0.1 M HCl 
[55, 
76, 
78, 
94, 
113] 
Kidney 
Human 
(Cortex) 
 1% SDS  Freytes 
[61] 
Liver 
Rat Perfusion  Freytes [57] 
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 1% Triton X-100 and 0.1% ammonium 
hydroxide 
 10% (w/w) pepsin  
 0.1 M HCl 
Rat, Porcine, Canine, 
Human 
 0.02% trypsin and 0.05% EGTA 
 3% Triton X-100 
 0.1% peracetic acid 
 Freytes 
 24-72 hr (until no 
particulate) 
[56] 
Porcine 
 0.02% trypsin and 0.05% EDTA 
 3% Triton X-100 
 4% sodium deoxycholic acid 
 0.1% peracetic acid 
 Freytes 
 72 hr 
[87, 
88] 
 0.1% SDS 
 Freytes 
 3 mg/mL pepsin 
 0.1 M HCl 
 72 hr 
[52] 
Lung 
Porcine 
Perfusion 
 1x pen/strep 
 0.1% Triton X-100 
 2% sodium deoxycholate 
 DNase solution 
 NaCl 
 Freytes 
[49] 
Pancreas 
Porcine 
 1.1% NaCl 
 0.7% NaCl 
 0.05% trypsin/0.02% EDTA, pH 8.2 
 1% Triton X-100/1% ammonium 
hydroxide 
 70% ethanol 
 Freytes 
 5 mg/mL pepsin 
 0.1 M HCl 
[62] 
Skeletal Muscle 
Porcine 
(Intercostal, Hindleg) 
 1% SDS 
 Freytes 
 0.1 M HCl 
[58, 
83] 
Porcine 
(Psoas) 
 1% SDS 
 1% SDS and 0.5% pen/strep 
 Isopropyl alcohol 
 Freytes 
 0.1 M HCl 
[104] 
 1% SDS and 0.5% pen/strep 
 Isopropyl alcohol 
 0.001% Triton X-100 
 Freytes 
 0.1 M HCl 
[63] 
Porcine 
 0.2% trypsin/0.1% EDTA 
 0.5% Triton X-100 
 1% Triton X-100/ 0.2% sodium 
deoxycholate 
 Isopropanol 
 5x107 U/l DNase-I and 1x106 U/l RNase 
 Freytes 
[64] 
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Skin 
Rat 
(Dermis) 
 2 mL dispase/ g tissue   Uriel 
[43-
46, 
65] 
Porcine 
(Dermis) 
 0.25% trypsin 
 70% ethanol 
 3% H2O2 
 1% Triton X-100 in 0.26% EDTA/0.69% 
Tris 
 0.1% peracetic acid/4% ethanol 
 Freytes 
 72 hr 
[23, 
114-
116] 
Small Intestine 
Porcine 
(Submucosa/muscularis 
mucosa/stratum 
compactum/lamina 
propria) 
Mechanical delamination of other tissue 
layers only 
 Voytik-Harbin 
 Additional step: 
centrifuged, 
dialyzed against 
0.01 M acetic acid 
[16, 
34] 
Porcine 
(Submucosa/muscularis 
mucosa/stratum 
compactum) 
 0.1% peracetic acid/4% ethanol 
 Freytes 
 72 hr 
[26, 
56, 
90, 
101] 
 0.1% peracetic acid/4% ethanol 
 Freytes 
 0.5 mg/mL pepsin 
[53] 
 0.1% peracetic acid/4% ethanol 
 Freytes 
 24 hr 
[51] 
Tendon 
Human 
(Flexor digitorum 
profudus, flexor 
digitorum superficialis, 
flexor pollicic longus) 
 0.1% EDTA 
 0.1% SDS in 0.1% EDTA 
 Freytes 
 0.02 M HCl 
 24 hr 
[59, 
84] 
Tooth  
Human 
(Dentin) 
 10% HCl 
 0.5% pen/strep 
 0.5M HCl 
 0.05% trypsin/0.025% EDTA 
 Freytes 
 84 hr 
[96] 
Umbilical Cord 
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Human 
 
 1% SDS and 0.5% pen/step 
 0.001% Triton X-100 
 40 U/mL DNase and 1 U/mL RNase in 
10 mM NaCl, 1 mM CaCl2 6 mM MgCl2, 
and 40 mM HCl 
 1% SDS and 0.5% pen/strep 
 0.001% Triton X-100 
 Freytes 
 0.1 M HCl 
[63] 
Urinary Bladder 
Porcine 
(Basement 
membrane/lamina 
propria) 
 0.1% peracetic acid/4% ethanol 
 
 Freytes 
[20-
24, 
54, 
56, 
82, 
91, 
93, 
99, 
101, 
116] 
Freytes: 
 1 mg/mL pepsin in 0.01 M HCl 
 Stir plate, RT, 48 hr 
 Neutralized to pH 7.4 and physiological salt with NaOH and 10x PBS 
 
Uriel: 
 High salt buffer solution (0.05 M Tris pH 7.4, 3.4 M sodium chloride, 4 mM of 
ethylenediaminete- traacetic acid, and 2 mM of N-ethylmaleimide) containing protease 
inhibitors (0.001mg/mL pepstatin, 0.01mg/mL aprotonin, 0.001mg/mL leupeptin, 2mM 
sodium orthova- nadate, and 1mM phenylmethylsulfonyl fluoride) 
 Homogenized with mortar and pestle 
 2 M urea buffer 
 
Voytik-Harbin: 
 2 mg pepsin per 100 mg ECM in 0.5 M acetic acid 
 4C, 72 hr 
 Neutralized to pH 7.4 and physiological salt with NaOH and 10x PBS 
 
Key 
Was not lyophilized/powdered prior to solubilization 
RT – room temperature 
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Table 2. Viscoelastic properties of porcine-derived ECM hydrogels. Italicized values 
were estimated from representative images. Steady shear viscosities refer to the pre-gel 
solution. “Pre-formed” indicates that gelation was induced in an incubator at 37oC prior 
to rheologic testing. * indicates time to 50% gelation. “NR” indicates “not recorded.” 
 
Tissue 
Conc. 
(mg/mL) 
Protocol 
(strain, frequency) 
G’ (Pa) 
Steady 
Shear 
Viscosity 
(Pa*s) 
Gelation 
time 
(min) 
Ref 
Cartilage 30 2%, 1 rad/s 4000 3  [73] 
Brain 
4 5%, 1 rad/s 20.3  34.8 [54] 
6 5%, 1 rad/s 49.9  2.4 [54] 
8 5%, 1 rad/s 61.8  8.3 [54] 
Colon 
4 0.5%, 1 rad/s 9 0.75  [71] 
8 0.5%, 1 rad/s 50 1.7  [71] 
Heart 
6 
2.5%, 0.4 rad/s 11.3 Pre-formed  [80] 
2.5%, 1 rad/s 6.5 Pre-formed  [78] 
NR, 1 rad/s, 5.28 Pre-formed  [42] 
NR, 6.28 rad/s 6.08 Pre-formed  [60] 
8 
2.5%, 0.5 rad/s 5.3 Pre-formed  [74] 
NR, 1 rad/s, 9.52 Pre-formed  [42] 
30 2%, 1 rad/s 800 33  [73] 
Liver 8 0.5%, 1 rad/s 630 4.25 8.5 [56] 
Lung 
4 0.5%, 6.28 rad/s 15.3   [49] 
6 0.5%, 6.28 rad/s 32.0   [49] 
8 0.5%, 6.28 rad/s 59.0   [49] 
Pancreas 16.7 2.5%, 1 rad/s 190  4.5 [62] 
Skeletal 
Muscle 
6 NR, 1 rad/s 6.5 Pre-formed  [83] 
Skin 
4 0.5%, 1 rad/s 110 2  [23] 
6 0.5%, 1 rad/s 200 2  [23] 
8 0.5%, 1 rad/s 466 7  [23] 
Spinal 
cord 
4 5%, 1 rad/s 138  11.7 [54] 
6 5%, 1 rad/s 235  7 [54] 
8 0.5%, 1 rad/s 757  28.9 [54] 
Urinary 
Bladder 
3 5%, 1 rad/s 6  10 [20] 
4 0.5%, 1 rad/s 110 0.06  [23] 
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76.6 0.084 3.2* [22] 
5%, 1 rad/s 11.4  52.5 [54] 
6 
0.5%, 1 rad/s 40 0.9  [23] 
5%, 1 rad/s 
26  10 [20] 
72.8  8.47 [54] 
8 
0.5%, 1 rad/s 
182 0.9  [23] 
460 0.443 3.0* [22] 
5%, 1 rad/s 143  19.8 [54] 
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Tendon                                 
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Umbilical Cord                              
[63] 
Urinary Bladder                
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Figure 1. Overview of techniques used to characterize and to evaluate the cellular response to ECM hydrogels thus far. 
ECM hydrogels derived from various species, concentrations and processing methods are categorized only by source 
tissue. 
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Figure 2. General approaches to assess cellular response to ECM hydrogels. The 
response of various cell types in vitro or in vivo can be evaluated 
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